MTOX Medtox Scientific, Inc. (MM)

Pomerantz Haudek Grossman & Gross LLP is investigating claims on behalf of investors of Medtox Scientific, Inc. (“Medtox” or the “Company”) (NASDAQ: MTOX) (ISIN: US5849772018) concerning the proposed acquisition of Medtox by Laboratory Corporation of America Holdings in a cash transaction valued at approximately $241 million.

The investigation concerns whether the Medtox directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value. Under the terms of the agreement, Medtox shareholders would receive $27.00 in cash per share of Medtox common stock. However, price to Revenues, Cash Flow and EBITDA are below that of comparable transactions.

Medtox shareholders seeking more information about this acquisition are advised to contact Rebecca Jarmon at rjarmon@pomlaw.com or 212-661-1100 or 888-476-6529, ext. 314.

The Pomerantz Firm, with offices in New York and Chicago, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 75 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of defrauded investors. See www.pomerantzlaw.com.

Medtox Scientific, Inc. (MM) (NASDAQ:MTOX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Medtox Scientific, Inc. (MM) (NASDAQ:MTOX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024